The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease
Monika Katko,1 Erika Galgoczi,1 Annamaria Erdei,1 Annamaria Gazdag,1 Eszter Berta,1 Miklos Bodor,1 Ildiko Seres,2 Ildiko Hircsu,1 Arpad Badics,1 Bernadett Ujhelyi,3 Livia Sira,1 Harjit Pal Bhattoa,4 Endre V Nagy1 1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Unive...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a0259d76a65c4987aca2af35bdb7aa38 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a0259d76a65c4987aca2af35bdb7aa38 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a0259d76a65c4987aca2af35bdb7aa382021-12-02T14:41:40ZThe 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease1178-7031https://doaj.org/article/a0259d76a65c4987aca2af35bdb7aa382021-05-01T00:00:00Zhttps://www.dovepress.com/the-4g5g-polymorphism-of-plasminogen-activator-inhibitor-type-1-is-a-p-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Monika Katko,1 Erika Galgoczi,1 Annamaria Erdei,1 Annamaria Gazdag,1 Eszter Berta,1 Miklos Bodor,1 Ildiko Seres,2 Ildiko Hircsu,1 Arpad Badics,1 Bernadett Ujhelyi,3 Livia Sira,1 Harjit Pal Bhattoa,4 Endre V Nagy1 1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 2Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 3Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 4Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HngaryCorrespondence: Endre V NagyDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, Debrecen, 4032, HungaryTel +36-30-337-1244Email nagy@internal.med.unideb.huIntroduction: Thyroid eye disease (TED) is an autoimmune disease of the orbits. Once developed, complete cure is rare. Plasminogen activator inhibitor type 1 (PAI-1) contributes to remodeling of connective tissue and has a central role in the pathogenesis of TED. We aimed to test if the 4G/5G polymorphism of PAI-1 is a predictor of the development of moderate-to-severe TED.Methods: A total of 185 patients with Graves’ disease, 87 of them with TED, 98 without TED, as well as 201 healthy controls, were studied. Genomic DNA was isolated from peripheral blood samples. The 4G/5G polymorphism of the PAI-1 gene was analyzed by allele-specific PCR, and the distribution of genotypes was calculated in each group. Plasma PAI-1 and thyroid hormone levels were measured by ELISA and ECLIA, respectively.Results: The 4G/4G genotype was associated with the development of moderate-to-severe TED (OR = 2.54; 95% CI: 1.26– 5.14; p < 0.01). The 4G/5G polymorphism of PAI-1 was not a predictor of plasma PAI-1 levels.Conclusion: The 4G/4G genotype of PAI-1 is a risk factor for the development of moderate-to-severe TED. Patients with Graves’ disease who harbor this genotype may be candidates for special attention towards the development of TED.Keywords: thyroid eye disease, Graves’ disease, PAI-1, 4G/5G polymorphism, risk factorKatko MGalgoczi EErdei AGazdag ABerta EBodor MSeres IHircsu IBadics AUjhelyi BSira LBhattoa HPNagy EVDove Medical Pressarticlethyroid eye diseasegraves’ diseasepai-14g/5g polymorphismrisk factorPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1883-1890 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
thyroid eye disease graves’ disease pai-1 4g/5g polymorphism risk factor Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
thyroid eye disease graves’ disease pai-1 4g/5g polymorphism risk factor Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Katko M Galgoczi E Erdei A Gazdag A Berta E Bodor M Seres I Hircsu I Badics A Ujhelyi B Sira L Bhattoa HP Nagy EV The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| description |
Monika Katko,1 Erika Galgoczi,1 Annamaria Erdei,1 Annamaria Gazdag,1 Eszter Berta,1 Miklos Bodor,1 Ildiko Seres,2 Ildiko Hircsu,1 Arpad Badics,1 Bernadett Ujhelyi,3 Livia Sira,1 Harjit Pal Bhattoa,4 Endre V Nagy1 1Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 2Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 3Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 4Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HngaryCorrespondence: Endre V NagyDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, Debrecen, 4032, HungaryTel +36-30-337-1244Email nagy@internal.med.unideb.huIntroduction: Thyroid eye disease (TED) is an autoimmune disease of the orbits. Once developed, complete cure is rare. Plasminogen activator inhibitor type 1 (PAI-1) contributes to remodeling of connective tissue and has a central role in the pathogenesis of TED. We aimed to test if the 4G/5G polymorphism of PAI-1 is a predictor of the development of moderate-to-severe TED.Methods: A total of 185 patients with Graves’ disease, 87 of them with TED, 98 without TED, as well as 201 healthy controls, were studied. Genomic DNA was isolated from peripheral blood samples. The 4G/5G polymorphism of the PAI-1 gene was analyzed by allele-specific PCR, and the distribution of genotypes was calculated in each group. Plasma PAI-1 and thyroid hormone levels were measured by ELISA and ECLIA, respectively.Results: The 4G/4G genotype was associated with the development of moderate-to-severe TED (OR = 2.54; 95% CI: 1.26– 5.14; p < 0.01). The 4G/5G polymorphism of PAI-1 was not a predictor of plasma PAI-1 levels.Conclusion: The 4G/4G genotype of PAI-1 is a risk factor for the development of moderate-to-severe TED. Patients with Graves’ disease who harbor this genotype may be candidates for special attention towards the development of TED.Keywords: thyroid eye disease, Graves’ disease, PAI-1, 4G/5G polymorphism, risk factor |
| format |
article |
| author |
Katko M Galgoczi E Erdei A Gazdag A Berta E Bodor M Seres I Hircsu I Badics A Ujhelyi B Sira L Bhattoa HP Nagy EV |
| author_facet |
Katko M Galgoczi E Erdei A Gazdag A Berta E Bodor M Seres I Hircsu I Badics A Ujhelyi B Sira L Bhattoa HP Nagy EV |
| author_sort |
Katko M |
| title |
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| title_short |
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| title_full |
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| title_fullStr |
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| title_full_unstemmed |
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease |
| title_sort |
4g/5g polymorphism of plasminogen activator inhibitor type 1 is a predictor of moderate-to-severe thyroid eye disease |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/a0259d76a65c4987aca2af35bdb7aa38 |
| work_keys_str_mv |
AT katkom the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT galgoczie the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT erdeia the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT gazdaga the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bertae the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bodorm the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT seresi the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT hircsui the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT badicsa the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT ujhelyib the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT siral the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bhattoahp the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT nagyev the4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT katkom 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT galgoczie 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT erdeia 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT gazdaga 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bertae 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bodorm 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT seresi 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT hircsui 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT badicsa 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT ujhelyib 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT siral 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT bhattoahp 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease AT nagyev 4g5gpolymorphismofplasminogenactivatorinhibitortype1isapredictorofmoderatetoseverethyroideyedisease |
| _version_ |
1718389887129878528 |